Latest News

Ampio Announces Early Positive Data in Phase 1 Trial of Inhaled Ampion in COVID-19 Respiratory Distress

Date: February 1, 2021 | READ MORE >

Ampio Pharmaceuticals Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19 with Ampion is 55% Enrolled

Date: January 14, 2021 | READ MORE >

Ampio Provides Update on Clinical Trials for Ampion™ Treatment of COVID-19 Patients

Date: January 4, 2021 | READ MORE >

AMPIO RECEIVES FEEDBACK FROM THE FDA ON AMPIO’S PROPOSED MODIFICATIONS TO THE SPECIAL PROTOCOL ASSSESSMENT FOR AMPION TREATMENT OF SEVERE OSTEOARTHRITIS OF THE KNEE

Date: December 29, 2020 | READ MORE >

Q&A Regarding Feedback from FDA

Date: December 29, 2020 | READ MORE >

Q&A with Dr. David Bar-Or on the COVID-19 Vaccines and the Variants

Date: December 23, 2020 | READ MORE >

Ampion Demonstrates Safety in COVID-19 Patients and Initiates Global Clinical Trial for Intravenous Ampion

Date: December 17, 2020 | READ MORE >

Ampio Enters into Collaborative Research Agreements to Explore Additional Clinical Indications for its Immunomodulatory Drug, Ampion

Date: December 10, 2020 | READ MORE >

Ampio Pharmaceuticals, Inc. to Host its Annual Meeting on December 12, 2020

Date: December 8, 2020 | READ MORE >

AMPIO’S PHASE I STUDY FOR INHALED AMPION ADVANCES TO COMPLETING ENROLLMENT OF COVID-19 PATIENTS WITH RESPIRATORY DISTRESS

Date: December 2, 2020 | READ MORE >

Ampio Updates Regulatory and Clinical Trial Events

Date: November 25, 2020 | READ MORE >

Ampio’s Phase I Study for Inhaled Ampion Advances to 3rd Group of COVID-19 Patients with Respiratory Distress

Date: November 17, 2020 | READ MORE >

AMPIO’S PHASE I STUDY FOR INHALED AMPION ADVANCES TO 2ND GROUP OF COVID-19 PATIENTS WITH RESPIRATORY DISTRESS

Date: November 10, 2020 | READ MORE >

Ampio Pharmaceuticals, Inc. Provides Business Update and Reports Third Quarter 2020 Financial Results

Date: November 5, 2020 | READ MORE >

Ampio Pharmaceuticals, Inc. to Host Conference Call on November 5th

Date: November 2, 2020 | READ MORE >

AMPIO BEGINS PHASE 1 CLINICAL TRIAL OF INHALED AMPION FOR COVID-19 PATIENTS WITH RESPIRATORY DISTRESS

Date: October 28, 2020 | READ MORE >

Ampio Pharmaceuticals, Inc. to Present at the ROTH Capital Healthcare Event “COVID-19 Therapeutics in Development”

Date: October 27, 2020 | READ MORE >

Ampio Presents at Roth Capital Partners 2020 MedTech Innovation Forum Focusing on COVID-19 Clinical Trial Activities

Date: October 26, 2020 | READ MORE >

Ampio Publication Reports Beneficial Effects of Ampion on Important Transcription Factors in Inflammation

Date: October 8, 2020 | READ MORE >

FDA Grants IND and Approves Clinical Trial Protocol of Inhaled Ampion for COVID-19 Patients with Respiratory Distress

Date: September 21, 2020 | READ MORE >